Our findings shed light on the role of SALL2 in the transcriptional regulation of ER, and present a potential clinical biosignature that could be used for subgrouping breast cancer patients and identify those who might benefit from co‐therapy with tamoxifen and DNMT inhibitor. Here, ESR1 is linked to breast cancer.